trial
as of 2026-07-01Comparison of a Long-acting Injectable Antipsychotic vs Clinician's Choice Early in Treatment to Break the Cycle of Relapse in Early Phase Schizophrenics
NCTId NCT02360319
at a glance
Phase 4 · Completed
Enrollment 489 (actual)
Sponsored by Vanguard Research Group
Primary completion 2019-03-31
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 4
Status
Completed
Enrollment
489 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Single
Start
2014-12-11
Primary completion
2019-03-31
Eligibility
ALL · 18 Years · 35 Years
Interventions & indications
Sponsors
Vanguard Research GroupLead Sponsor
Investigators
1
John W. Newcomer, M.D.Principal Investigator
Sites
39 total
Tucson, United StatesGranada Hills, United StatesPalo Alto, United StatesFort Lauderdale, United StatesGainesville, United StatesJacksonville, United StatesLeesburg, United StatesSt. Petersburg, United StatesTallahassee, United StatesWest Palm Beach, United StatesAtlanta, United StatesAugusta, United States
Facts & assertions
4 sourced
Enrollment
489
Phase
PHASE4
Primary Completion Date
2019-03-31
Status
COMPLETED
relationships
The graph out of here
drug
lead_sponsor
company
collaborator
indication
indication
indication
investigator
person